The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients

Diabetologia

Volumn 49, Issue 6, 2006, Pages 1394-1401

  Braschi, S ^a   Geoffrion, M ^b   Nguyen, A ^b   Gaudreau, Y ^c   Milne, R W ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c Hull Hospital   (Canada)

Author keywords

AGE; Apolipoprotein B; Diabetes; End stage renal disease; LDL

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B100; APOLIPOPROTEIN B100 ANTIBODY; EPITOPE; GLUCOSE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLYCATION; HUMAN; IMMUNOREACTIVITY; IN VIVO STUDY; KIDNEY FAILURE; KIDNEY FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPRODUCIBILITY;

APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; PROTEIN ISOFORMS; REFERENCE VALUES; TRIGLYCERIDES;

EID: 33646530952     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0217-4     Document Type: Article

References (40)

1. Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689-697
2. Schwedler SB, Metzger T, Schinzel R, Wanner C (2002) Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62:301-310
3. Thornalley PJ, Battah S, Ahmed N et al (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375:581-592
4. Thornalley PJ, Langborg A, Minhas HS (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 344:109-116
5. Sasaki J, Arora V, Cottam GL (1982) Nonenzymatic galacto-sylation of human LDL decreases its metabolism by human skin fibroblasts. Biochem Biophys Res Commun 108:791-796
6. Lorenzi M, Cagliero E, Markey B, Henriksen T, Witztum JL, Sampietro T (1984) Interaction of human endothelial cells with elevated glucose concentrations and native and glycosylated low density lipoproteins. Diabetologia 26:218-222
7. Klein RL, Laimins M, Lopes-Virella MF (1995) Isolation, characterization, and metabolism of the glycated and non-glycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 44:1093-1098
8. Lam MC, Tan KC, Lam KS (2004) Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages. Atherosclerosis 177:313-320
9. Ravandi A, Kuksis A, Shaikh NA (1999) Glycated phosphatidylethanolamine promotes macrophage uptake of low density lipoprotein and accumulation of cholesteryl esters and triacylglycerols. J Biol Chem 274:16494-16500
10. Bucala R, Makita Z, Vega GL, Grundy SM, Koschinsky T, Cerami A (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91:9441-9445
11. Ravandi A, Kuksis A, Shaikh NA (2000) Glucosylated glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation: evidence of their presence in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 20:467-477
12. Baynes JW (1991) Role of oxidative stress in development of complications of diabetes. Diabetes 40:405-412
13. Bucala R (1997) Lipid and lipoprotein modification by advanced glycosylation end-products: role in atherosclerosis. Exp Physiol 82:327-337
14. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H (1994) Lipid advanced glycosylation: pathway for lipid oxidation in vitro. Proc Natl Acad Sci USA 90:6434-6438
15. Wang X, Bucala R, Milne R (1998) Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products. Proc Natl Acad Sci USA 95:7643-7647
16. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
17. Havel RJ (1998) Receptor and non-receptor mediated uptake of chylomicron remnants by the liver. Atherosclerosis 141:S1-S7
18. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275
19. Pease RJ, Milne RW, Jessup WK et al (1989) Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem 265:553-568
20. Wang XY, Chauhan V, Nguyen AT et al (2003) Immunochemical evidence that human apoB differs when expressed in rodent versus human cells. J Lipid Res 44:547-553
21. Cohen MP, Lautenslager G, Shea E (1993) Glycated LDL concentrations in non-diabetic and diabetic subjects measured with monoclonal antibodies reactive with glycated apolipoprotein B epitopes. Eur J Clin Chem Clin Biochem 31:707-713
22. Shea EA, Cohen MP (1993) Immunologic detection and measurement of glycated apolipoprotein B with site specific monoclonal antibodies. J Immunol Methods 162:85-95
23. Wang X, Peesapati SK, Renedo MF, Moktan S (2004) Hemoglobin A1c levels in non-diabetic patients with end-stage renal disease (ESRD) receiving hemodialysis. J Endocrinol Invest 27:733-735
24. Bucala R (1996) Lipid and lipoprotein oxidation: basic mechanisms and unresolved questions in vivo. Redox Rep 2:291-307
25. Jenkins AJ, Thorpe SR, Alderson NL et al (2004) In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism 53:969-976
26. Wang XY, Pease R, Bertinato J, Milne RW (2000) Well-defined regions of apolipoprotein B-100 undergo conformational change during its intravascular metabolism. Arterioscler Thromb Vasc Biol 20:1301-1308
27. Gugliucci CA, Dumont S, Siffert JC, Stahl AJ (1992) In vitro glycated low-density lipoprotein interaction with human monocyte-derived macrophages. Res Immunol 143:17-23
28. Shimano H, Yamada N, Ishibashi S et al (1991) Oxidation-labile subfraction of human plasma low density lipoprotein isolated by ion-exchange chromatography. J Lipid Res 32:763-773
29. Stahl AJ, Rima A, Blickle JF, Brogard JM (1998) Short-term variations of serum glycated apolipoprotein B. Diabetes Metab 24:151-155
30. Avogaro P, Bon GB, Cazzolato G (1988) Presence of a modified low density lipoprotein in humans. Arteriosclerosis 8:79-87
31. Kaplan M, Aviram M (2001) Retention of oxidized LDL by extracellular matrix proteoglycans leads to its uptake by macrophages: an alternative approach to study lipoproteins cellular uptake. Arterioscler Thromb Vasc Biol 21:386-393
32. Proctor SD, Mamo JC (2003) Intimal retention of cholesterol derived from apolipoprotein. Arterioscler Thromb Vasc Biol 23:1595-1600
33. Tabas I (1999) Nonoxidative modifications of lipoproteins in atherogenesis. Annu Rev Nutr 19:123-139
34. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H (1990) Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc Natl Acad Sci USA 87:9010-9014
35. Dobrian A, Lazar V, Tirziu D, Simionescu M (1996) Increased macrophage uptake of irreversibly glycated albumin modified low density lipoproteins of normal and diabetic subjects is mediated by non-saturable mechanisms. Biochim Biophys Acta 1317:5-14
36. Brizzi MF, Dentelli P, Gambino R et al (2002) STAT5 activation induced by diabetic LDL depends on LDL glycation and occurs via src kinase activity. Diabetes 51:3311-3317
37. Rabini RA, Cester N, Staffolani R et al (1999) Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. Diabetes 48:2221-2228
38. Ahmed N, Dobler D, Dean M, Thornalley PJ (2005) Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 280:5724-5732
39. 2+ and glucose induced oxidation. Biopolymers 72:514-520
40. Kramer-Guth A, Quaschning T, Galle J et al (1997) Structural and compositional modifications of diabetic low-density lipoproteins influence their receptor-mediated uptake by hepatocytes. Eur J Clin Invest 27:460-468